Emergence of Concurrent Multiple Mutations and Amplification in a Patient With -Amplified Advanced Gastric Cancer Treated With Cetuximab.
作者信息
Nakamura Yoshiaki, Sasaki Akinori, Yukami Hiroki, Jogo Tomoko, Kawazoe Akihito, Kuboki Yasutoshi, Taniguchi Hiroya, Yamashita Riu, Kuwata Takeshi, Ozawa Miho, Nakamura Maho, Yoshino Takayuki, Shitara Kohei
机构信息
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Translational Research Support Section, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
出版信息
JCO Precis Oncol. 2020 Nov 17;4. doi: 10.1200/PO.20.00263. eCollection 2020.
Abstract
摘要
相似文献
1
Emergence of Concurrent Multiple Mutations and Amplification in a Patient With -Amplified Advanced Gastric Cancer Treated With Cetuximab.西妥昔单抗治疗的HER2扩增晚期胃癌患者出现同时发生的多种突变和扩增
JCO Precis Oncol. 2020 Nov 17;4. doi: 10.1200/PO.20.00263. eCollection 2020.
2
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.Tivantinib 和 Cetuximab 治疗 EGFR 抑制剂获得性耐药并出现 MET 过表达的 KRAS 野生型转移性结直肠癌患者的 II 期研究：为未来 EGFR/MET 双重抑制试验提供的经验教训。
Clin Colorectal Cancer. 2019 Jun;18(2):125-132.e2. doi: 10.1016/j.clcc.2019.02.004. Epub 2019 Feb 14.
3
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.表皮生长因子受体荧光原位杂交（EGFR FISH）阳性的结直肠癌患者对西妥昔单抗治疗的原发性耐药
Br J Cancer. 2008 Jul 8;99(1):83-9. doi: 10.1038/sj.bjc.6604439. Epub 2008 Jun 24.
4
Evaluation of epidermal growth factor receptor signaling effects in gastric cancer cell lines by detailed motility-focused phenotypic characterization linked with molecular analysis.通过与分子分析相关的详细运动聚焦表型特征评估胃癌细胞系中表皮生长因子受体信号传导效应。
BMC Cancer. 2017 Dec 13;17(1):845. doi: 10.1186/s12885-017-3822-3.
5
The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR.通过定量实时聚合酶链反应检测表皮生长因子受体（EGFR）、ErbB2和间质-上皮转化因子（MET）基因扩增对人胃癌的预后影响。
J Cancer Res Clin Oncol. 2015 Nov;141(11):1945-52. doi: 10.1007/s00432-015-1965-7. Epub 2015 Mar 29.
6
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.结直肠癌患者接受西妥昔单抗治疗时出现多种 EGFR 胞外突变。
Clin Cancer Res. 2015 May 1;21(9):2157-66. doi: 10.1158/1078-0432.CCR-14-2821. Epub 2015 Jan 26.
7
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.双重MET/EGFR疗法在MET扩增的胃食管异种移植患者队列中可导致完全缓解并预防耐药。
Oncogene. 2017 Mar 2;36(9):1200-1210. doi: 10.1038/onc.2016.283. Epub 2016 Aug 15.
8
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.MET 受体扩增导致结直肠癌对抗 EGFR 治疗产生耐药性。
Cancer Discov. 2013 Jun;3(6):658-73. doi: 10.1158/2159-8290.CD-12-0558. Epub 2013 Jun 2.
9
Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells.西妥昔单抗联合 S-1 在表皮生长因子受体扩增胃癌细胞中的抗肿瘤作用。
Int J Oncol. 2012 Apr;40(4):975-82. doi: 10.3892/ijo.2011.1279. Epub 2011 Dec 1.
10
Distinct Characteristics and Clinical Outcomes to Predict the Emergence of Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.预测接受表皮生长因子受体酪氨酸激酶抑制剂治疗后出现耐药的非小细胞肺癌患者中扩增出现的独特特征和临床结局
Cancers (Basel). 2021 Jun 21;13(12):3096. doi: 10.3390/cancers13123096.
引用本文的文献
1
Clinical Significance of Extrachromosomal DNA in -Amplified Gastric Cancer: Therapeutic Implications From Clinical Experience.扩增型胃癌中染色体外DNA的临床意义：基于临床经验的治疗启示
JCO Precis Oncol. 2025 Aug;9:e2500033. doi: 10.1200/PO-25-00033. Epub 2025 Aug 18.
2
A Case of Advanced Biliary Tract Cancer With EGFR Amplification That Responded to Necitumumab.一例存在 EGFR 扩增的晚期胆道癌对尼妥珠单抗治疗有响应。
Cancer Rep (Hoboken). 2024 Nov;7(11):e70053. doi: 10.1002/cnr2.70053.
3
Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer.基于生物标志物的晚期胃癌靶向治疗及免疫检查点抑制剂的研究进展与展望
Front Oncol. 2024 Jun 14;14:1382183. doi: 10.3389/fonc.2024.1382183. eCollection 2024.
4
EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma.表皮生长因子受体和 PI3K 信号通路作为转移性胃腺癌患者循环肿瘤细胞的有前途的靶点。
Int J Mol Sci. 2024 May 20;25(10):5565. doi: 10.3390/ijms25105565.
5
New therapeutic target molecules for gastric and gastroesophageal junction cancer.胃癌和胃食管结合部癌的新治疗靶点分子。
Int J Clin Oncol. 2024 Sep;29(9):1228-1236. doi: 10.1007/s10147-024-02521-3. Epub 2024 Apr 17.
6
Opportunities and challenges of targeting c-Met in the treatment of digestive tumors.靶向c-Met在消化系统肿瘤治疗中的机遇与挑战
Front Oncol. 2022 Aug 1;12:923260. doi: 10.3389/fonc.2022.923260. eCollection 2022.
7
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.表皮生长因子受体抑制剂在表皮生长因子受体扩增的胃食管交界处癌中的应用：回顾性全球经验。
J Clin Oncol. 2022 Aug 1;40(22):2458-2467. doi: 10.1200/JCO.21.02453. Epub 2022 Mar 29.
8
Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond.化学难治性胃癌：三线及后续治疗的发展态势
Cancers (Basel). 2022 Mar 10;14(6):1408. doi: 10.3390/cancers14061408.
9
Circulating Tumor DNA Analysis Detects Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer.循环肿瘤 DNA 分析检测晚期胃癌中与 FGFR 抑制剂疗效相关的扩增和同时发生的基因组改变。
Clin Cancer Res. 2021 Oct 15;27(20):5619-5627. doi: 10.1158/1078-0432.CCR-21-1414. Epub 2021 Aug 10.
10
EGFR Amplification in Metastatic Colorectal Cancer.转移性结直肠癌中的 EGFR 扩增。
J Natl Cancer Inst. 2021 Nov 2;113(11):1561-1569. doi: 10.1093/jnci/djab069.
本文引用的文献
1
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.液体活检与组织活检在检测胃肠道癌获得性耐药及肿瘤异质性中的应用。
Nat Med. 2019 Sep;25(9):1415-1421. doi: 10.1038/s41591-019-0561-9. Epub 2019 Sep 9.
2
Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.胃食管腺癌的循环肿瘤 DNA 测序分析。
Clin Cancer Res. 2019 Dec 1;25(23):7098-7112. doi: 10.1158/1078-0432.CCR-19-1704. Epub 2019 Aug 19.
3
Revisiting Epidermal Growth Factor Receptor () Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies.重新审视表皮生长因子受体（）扩增作为抗表皮生长因子受体治疗靶点：晚期恶性肿瘤患者游离循环肿瘤DNA分析
JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00180. Epub 2019 Jan 22.
4
and Amplifications Determine Response to HER2 Inhibition in -Amplified Esophagogastric Cancer.和扩增决定了对 HER2 抑制在 - 扩增食管胃交界癌的反应。
Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21.
5
Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.采用阿法替尼和克唑替尼联合治疗一名患有EGFR突变及伴发MET外显子14跳跃突变的非小细胞肺癌患者并获成功
Clin Lung Cancer. 2019 Jan;20(1):59-62. doi: 10.1016/j.cllc.2018.09.009. Epub 2018 Sep 21.
6
Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.分析转移性结直肠癌患者循环肿瘤 DNA 的临床实用性。
Oncologist. 2018 Nov;23(11):1310-1318. doi: 10.1634/theoncologist.2017-0621. Epub 2018 Apr 26.
7
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for -Amplified Gastroesophageal Adenocarcinoma.针对特定人群的靶向治疗：抗 EGFR 治疗 - 扩增型胃食管腺癌。
Cancer Discov. 2018 Jun;8(6):696-713. doi: 10.1158/2159-8290.CD-17-1260. Epub 2018 Feb 15.
8
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.Sym004 治疗经抗 EGFR 治疗获得性耐药且经循环肿瘤 DNA 分析分子选择的转移性结直肠癌患者的疗效：一项 2 期随机临床试验。
JAMA Oncol. 2018 Apr 12;4(4):e175245. doi: 10.1001/jamaoncol.2017.5245.
9
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.基因组异质性是胃食管腺癌精准医疗的障碍。
Cancer Discov. 2018 Jan;8(1):37-48. doi: 10.1158/2159-8290.CD-17-0395. Epub 2017 Oct 4.
10
Assessment of EGFR and ERBB2 (HER2) in Gastric and Gastroesophageal Carcinomas: EGFR Amplification is Associated With a Worse Prognosis in Early Stage and Well to Moderately Differentiated Carcinoma.胃癌和胃食管癌中表皮生长因子受体（EGFR）和 erb-b2 受体酪氨酸激酶 2（ERBB2，即 HER2）的评估：EGFR 扩增与早期及高分化至中分化癌的预后较差相关。
Appl Immunohistochem Mol Morphol. 2018 Jul;26(6):374-382. doi: 10.1097/PAI.0000000000000437.
Zotero 插件